Happy New Year! Year End Charts.
Expect 2024 to be Year of Both Massive of Gains (and Losses) Plus Massive Volatility. Be Prepared!
Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024
LYMPHIR™ BLA resubmission on track for early 2024
Pharmather (PHRRF) Has Officially Broken Out.
Read Corporate Presentation Today.
Pharmather (PHRRF) which we gave a 'heads-up,' because looked like it was about to break...
Post Reverse Split Mania!
Now Wait a Minute, Aren't Stocks That do Reverse Splits Supposed go Down and Stay Down?
First our...
Adding Geovax (GOVX) to 2024 Biotech Watch List.
GEOVAX (GOVX) $0.32
We added this to the Watch List earlier in the...
LQR House (LQR) Commits to Postpone Public Offerings for the Foreseeable Future.
LQR House Initiates Warrants Cancellation and Commits to Postpone Public Offerings for the Foreseeable Future
GeoVax Labs (GOVX) Video Presentation.
GeoVax’s COVID-19 vaccine candidates, which can induce strong antibody and T cell responses against the variants of the SARS-CoV-2 virus, also offers...
PharmaTher (PHRRF) Breaks Above Resistance.
We're now up 325% in just Under a Year. Last "big" News was Receiving a Priority Original Abbreviated New Drug Application,...
Five Myths About Ketamine and Matthew Perry’s Death (Fox News).
Through the first nine months of the year, global Johnson and Johnson's Spravato Ketamine nasal-spray revenues were $483 million, an 88.8%...
LQR House (LQR) +65%, Rebounding On New Clients Announcements.
The Liquor House Continues to Impress.
We called this the most interesting Company of 2023. While extreme volume...